Skip to main content
Livermore
Livermore
ZHEN

Weaver Consulting Group

SEC CIK
0001780055
Latest filing
Jul 29, 2026

BCLI holding history

Brainstorm Cell Therapeutics Inc. in every 13F filed by Weaver Consulting Group, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

BCLI overviewAll 13F holders of BCLIFull Q2 2026 holdings

Shares (Q3 2025)
0
Sold out in Q3 2025
Value
$0
% of portfolio
0.0%
Quarters held
18
Since Q1 2021
Holdings of BCLI by Weaver Consulting Group, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q3 20250$00.0%−15,623−100.0%Sold outHolders
Q2 202515,623$17.5K<0.1%00.0%UnchangedHolders
Q1 202515,623$19.7K<0.1%00.0%UnchangedHolders
Q4 202415,623$35.5K<0.1%00.0%UnchangedConverted for a 1-for-15 splitHolders
Q3 2024234,356$54.0K<0.1%00.0%UnchangedHolders
Q2 2024234,356$79.3K<0.1%+35,000+17.6%AddedHolders
Q1 2024199,356$112.6K<0.1%00.0%UnchangedHolders
Q4 2023199,356$54.4K<0.1%+100,000+100.6%AddedHolders
Q3 202399,356$19.9K<0.1%+34,643+53.5%AddedHolders
Q2 202364,713$133.3K0.1%+1,000+1.6%AddedHolders
Q1 202363,713$210.3K0.1%−2,234−3.4%ReducedHolders
Q4 202265,947$108.2K0.1%−28,025−29.8%ReducedHolders
Q3 202293,972$415.0K0.2%−10,681−10.2%ReducedHolders
Q2 2022104,653$289.0K0.2%−25,347−19.5%ReducedHolders
Q1 2022130,000$437.0K0.2%−25,500−16.4%ReducedHolders
Q4 2021155,500$622.0K0.3%+104,000+201.9%AddedHolders
Q3 202151,500$170.0K0.1%+2,619+5.4%AddedHolders
Q2 202148,881$186.0K0.1%−1,119−2.2%ReducedHolders
Q1 202150,000$192.0K0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.